##  [Third Novartis Phase III trial shows Kisqali® combination therapy significantly improves PFS in HR+/HER2- advanced breast cancer](/us-en/news/media-releases/third-novartis-phase-iii-trial-shows-kisqali-combination-therapy-significantly-improves-pfs-hrher2-advanced-breast-cancer-0 "Third Novartis Phase III trial shows Kisqali® combination therapy significantly improves PFS in HR+/HER2- advanced breast cancer") 

  Jun 03, 2018